Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age

NCT00397215 PHASE2 COMPLETED Results posted

The present study is designed to evaluate the immunogenicity and safety of a single or double dose of the pandemic influenza candidate vaccine (GSK1562902A), administered following a two-administration schedule (21 days apart) in adults over 60 years of age. The persistence of influenza antibodies will also be evaluated 24 months after vaccination.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	COMPLETED
Enrolment	437
Start date	Fri Nov 17 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Sep 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Influenza

Interventions

• Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)
• Fluarix

Countries

Belgium, Italy